Obinutuzumab | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Obinutuzumab
Health Canada Patents

Veranova: A CDMO that manages complexity with confidence.

Contact Supplier

Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

Contact Supplier

pharmacompass-1-m-2025-08-25

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Obinutuzumab

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

219 Drugs in Development

219 Drugs in Development

FINISHED DOSAGE FORMULATIONS

19 FDF Dossiers, 1 FDA Orange Book, 2 Europe, 1 Canada, 14 Australia, 1 South Africa

19 FDF Dossiers
1 FDA Orange Book
2 Europe
1 Canada
14 Australia
1 South Africa

DIGITAL CONTENT

1 Stock Recap #PipelineProspector, 57 News #PharmaBuzz

1 Stock Recap #PipelineProspector
57 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Regulatory FDF Prices, 9 Annual Reports

1 US Medicaid Prescriptions
1 Regulatory FDF Prices
9 Annual Reports

PATENTS & EXCLUSIVITIES

4 Health Canada Patents

4 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4Gowling WLG (Canada) LLP

filter Patent Reset all filters

4 All

01 12544865

02 12708869

03 12716884

04 12769674

filter Product Reset all filters

4 All

01 4OBINUTUZUMAB

filter Dosage Reset all filters

4 All

01 4SOLUTION

filter Exp Date Reset all filters

4 All

01 12024-11-05

02 12028-12-11

03 12029-03-23

04 12030-08-12

Product Main Page

01

Gowling WLG (Canada) LLP

Obinutuzumab

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Canada

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2028-12-11

Date Granted : 2016-06-28

Obinutuzumab

Brand Name : GAZYVA

Patent Number : 2708869

Filing Date : 2008-12-11

Strength per Unit : 25mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2028-12-11

Date Granted : 2016-06-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Gowling WLG (Canada) LLP

Obinutuzumab

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-03-23

Date Granted : 2017-10-03

Obinutuzumab

Brand Name : GAZYVA

Patent Number : 2716884

Filing Date : 2009-03-23

Strength per Unit : 25mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2029-03-23

Date Granted : 2017-10-03

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Gowling WLG (Canada) LLP

Obinutuzumab

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-11-05

Date Granted : 2019-07-09

Obinutuzumab

Brand Name : GAZYVA

Patent Number : 2544865

Filing Date : 2004-11-05

Strength per Unit : 25mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2024-11-05

Date Granted : 2019-07-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Gowling WLG (Canada) LLP

Obinutuzumab

Peptide Process CMC

Not Confirmed

Gowling WLG (Canada) LLP

Country

Peptide Process CMC

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-12

Date Granted : 2018-01-23

Obinutuzumab

Brand Name : GAZYVA

Patent Number : 2769674

Filing Date : 2010-08-12

Strength per Unit : 25mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : INTRAVENOUS

Patent Expiration Date : 2030-08-12

Date Granted : 2018-01-23

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!